apalutamideLevothyroxineprostate cancerMambrino XXISIGLOPCFarmis
…ent, and outcomes of hypothyroidism in PC patients treated with apalutamide.Material and Methods This retrospective observational study inc…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 72 of 2459amikacinteicoplaninlinezolidoxacillinmetronidazolevancomycincefiximecefiderocolAntimicrobial resistanceazithromycin+6 more
… metronidazole (+415.26%), ampicillin/sulbactam (+367.20%), and amikacin (+177.96%), while lowest consumption was observed for oxacillin…
ECOG Performance StatusbevacizumabmCRCmetastatic colorectal cancerFTD-TPIBEV
…e mainly used as a third-line treatment (89%) for patients with ECOG performance status of 0-1 (86%) primarily. The average number of cycles administer…
afliberceptranibizumabAMDdiabetic macular oedemaDMEage-related macular degeneration
…and DME are leading causes of vision loss, with ranibizumab and aflibercept as key treatments. However, frequent monthly injections create …
quetiapineprednisoneclomipraminecetirizineclonazepamsertralinemetforminfamotidinefurosemidemirtazapine+6 more
…in, famotidine, fentanyl, hydroxyzine, mirtazapine, prednisone, quetiapine.Anticholinergic risk varied depending on the scale used. The pr…
vedolizumabustekinumabinfliximabVirgen Macarena University HospitalCrohn’s diseaseIBDinflammatory bowel disease
…4 were 51.5% and 45.8% for ustekinumab, and 58.7% and 55.4% for vedolizumab, respectively. In Crohn’s disease, prior infliximab use, male s…
urothelial carcinomaNivolumab-CTnivolumabgemcitabine-cisplatinpembrolizumabEV-Pembrolizumabenfortumab vedotinEuropean Medicines AgencyUCgemcitabine
…ab in combination with gemcitabine-cisplatin (Nivolumab-CT) for urothelial carcinoma (UC). Indirect comparisons between these regimens might support…
Colorectal cancerUK BiobankCRCcardiovascular disease
…Objective Colorectal cancer (CRC) and cardiovascular disease (CVD) share common risk factor…
axSpAPsAankylosing spondylitispsoriatic arthritisarthropathic psoriasisaxial spondyloarthritis
…r necrosis factor (TNF) inhibitors, reduced mortality by 47% in axSpA and 38% in PsA compared with untreated patients.Conclusion All-…
SLEhydroxychloroquineDiabetes mellitusRSR ltdGAD AbZnT8 AbSLEDAI-2Kimmunosuppressants
…ed antibodies (DMa Ab) were detected in 9 (17.6%) patients with SLE: only ZnT8 Ab in 4 (7.8%), only GAD Ab in 4 (7.8%) women, and Z…
SLESLE-DASanifrolumabMSDAAstraZeneca
…ue for HR-QoL supports its use as a next-generation endpoint in SLE trials. SLE-DAS accurately classifies MSDA, supporting use in e…